AMGN — Amgen
Type: stock | Currency: USD | Sector: Health Care
Analysis update required
The stored signal has incomplete price provenance. It is shown only as historical information. ADD is the original model label, not a newly validated BUY.
Experimental technical research, not a fair-value assessment or personalized investment recommendation.
Stored assessment, historical plan and data provenance
Original action: ADD
Signal recorded at: 2026-11-18T07:56:27.558316+00:00
Data fetched at: N/A
Engine: N/A
Price basis: N/A
Technical score: N/A — not a probability
Why this assessment?
Fused signal based on technical setup and 10 recent news articles. News bias: 0.29, news strength: 0.52.
Time horizon: Days to weeks — fixed heuristic, not a forecast
Targets are stored technical levels, not estimates of intrinsic value. Previous stop/target events have not been integrated into this screen.
The temporary age rule flags prices more than three calendar days old. It is not exchange-calendar validation.
Calculation metadata
{}View scores, stored reasons and news
Latest stored ranking
Date: 2026-11-18
Stored rank: 27
Stored overall: 60.37
Model classification: watchlist
The overall score is experimental, not a fair-value estimate or investment recommendation.
Latest scores
Score date: 2026-11-18
Safety proxy: higher means better on the selected risk indicators; it does not measure total investment risk.
Heuristic value-trap flag: False
View full score breakdown and raw metrics
{
"risk": {
"leverage_score": 0.0,
"liquidity_score": 0.5658333333333334,
"volatility_score": 1.0
},
"value": {
"pb_score": 0.0,
"pe_score": 0.33813332000000007,
"dividend_score": 1.0,
"ev_ebitda_score": 0.2597857142857143
},
"quality": {
"roe_score": 1.0,
"growth_score": 0.5666666666666668,
"margin_score": 1.0
},
"raw_metrics": {
"beta": 0.417,
"ev_ebitda": 16.363,
"forward_pe": 18.260271,
"net_margin": 0.24139999,
"trailing_pe": 26.546667,
"current_ratio": 1.479,
"price_to_book": 17.258234,
"debt_to_equity": 376.303,
"dividend_yield": 2.18,
"revenue_growth": 0.085,
"operating_margin": 0.34120998,
"return_on_equity": 0.78353
}
}
Latest active signal
Signal date: 2026-11-18T07:56:27.558316+00:00
Type: tactical
Action label: add
Model confidence: 53.00
Confidence is a heuristic model output, not a calibrated probability of profit.
Fused signal based on technical setup and 10 recent news articles. News bias: 0.29, news strength: 0.52.
Stored reasons
- news: Positive recent news supports the existing technical setup | Moderate news impact detected | Technical confidence: 50.00 | News bias: 0.29 | News strength: 0.52 | Fused confidence: 53.00 | Recent articles analyzed: 10 | Previous technical action: hold
Latest stored news
-
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
Yahoo | 2026-11-17T17:00:00+00:00
Keyword sentiment: 0.67 | Keyword impact: 2.00 -
Can Regeneron Stock Hit $1,400?
Yahoo | 2026-11-17T16:13:44+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13
Yahoo | 2026-11-17T13:05:02+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Was Eli Lilly Stock's 45% Run Visible Early?
Yahoo | 2026-11-17T12:38:59+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Amgen (AMGN) Just Gave Investors Something To Think About
Yahoo | 2026-11-16T23:12:32+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
The Winners Inside SCHD - November 2026
SeekingAlpha | 2026-11-16T22:36:40+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Should You Trim Or Add To Your Viking Therapeutics Position?
Yahoo | 2026-11-16T21:46:03+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness
Yahoo | 2026-11-16T19:59:32+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
Yahoo | 2026-11-16T18:06:31+00:00
Keyword sentiment: -0.33 | Keyword impact: 1.00 -
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
Yahoo | 2026-11-16T18:02:00+00:00
Keyword sentiment: 0.33 | Keyword impact: 1.00